Gilead Sciences Q2 Net Income Rises

Gilead Sciences (GILD) reported Q2 2025 net sales of $7.1 billion, an increase from $6.9 billion year-over-year, with net income rising to $1.9 billion ($1.56/share). The biopharmaceutical company also raised its full-year 2025 product sales guidance to $28.3 billion-$28.7 billion and its non-GAAP diluted EPS forecast to $7.95-$8.25, primarily driven by stronger expectations for product sales excluding Veklury, despite a reduced Veklury sales projection. Following the announcement, GILD shares were trading up 2.93% on the NasdaqGS.

Analysis

Gilead Sciences reported a positive second quarter for 2025, characterized by modest revenue growth and a significant upward revision to its full-year guidance. Net sales for the quarter increased to $7.1 billion from $6.9 billion year-over-year, while GAAP net income rose to $1.9 billion, or $1.56 per share. However, the operational performance presented a more nuanced picture, with adjusted net income remaining flat at $2.01 per share and operating income experiencing a slight decline to $2.4 billion. The key driver for the positive market reaction, evidenced by a 2.93% after-hours share price increase, is the strengthened full-year outlook. Gilead raised its non-GAAP diluted EPS forecast to a range of $7.95 to $8.25, supported by an improved forecast for product sales excluding Veklury, which are now expected to be between $27.3 billion and $27.7 billion. This demonstrates underlying strength in the company's core portfolio, which is more than offsetting the expected decline in its COVID-19 treatment, Veklury, whose sales forecast was cut from $1.4 billion to $1.0 billion.

Key Decisions for Investors

• Investors should focus on the upgraded full-year guidance for non-GAAP EPS and ex-Veklury sales, as these figures indicate a strengthening core business that is the primary driver of the positive market sentiment.
• It is crucial to monitor the growth trajectory of the non-Veklury product portfolio in subsequent quarters, as the downward revision of Veklury's forecast confirms its diminishing contribution and shifts the focus entirely to the performance of other key assets.
• While the overall outlook is positive, the slight decline in Q2 operating income and flat adjusted earnings warrant attention; investors should scrutinize future reports for any signs of sustained margin pressure or increasing operational costs.